DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction

Information source: Mahidol University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Analgesia After ACL Reconstruction

Intervention: 0.25% Bupivacaine (Drug); 0.5% Bupivacaine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Mahidol University

Official(s) and/or principal investigator(s):
arissara iamaroon, Principal Investigator, Affiliation: Mahidol University


Femoral nerve block using 0. 25% bupivacaine or 0. 5% bupivacaine provides a longer time for analgesia after Anterior Cruciate Ligament (ACL) reconstruction.

Clinical Details

Official title: Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: time to first analgesic requirement

Secondary outcome: pain score scale


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients scheduled for ACL reconstruction

- ASA physical status I-II

- Body weight > or = 50 kg.

Exclusion Criteria:

- Patients with redo ACL reconstruction

- Contraindication to neuraxial block

- allergy to local anesthetics, sulfa, NSAIDs, morphine, paracetamol

- Patients with communication problem

Locations and Contacts

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Additional Information

Starting date: April 2011
Last updated: April 8, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017